Core-shell silica and fluorogenic hyaluronan nanomaterials in magnesium hydroxyapatite scaffolds for bone regeneration
Calabrese G., Genovese D., Morganti D., Rizzo MG., Sciuto EL., Nicotra G.
Animal Study, published in Sci Rep (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Sci Rep (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 41224808
- PMCID
- PMC12612038
- DOI
- 10.1038/s41598-025-21902-w
Abstract (original English)
Nanomaterials represents a class of multifunctional materials that can play a key role in multiple applications of biomedicine. In case of severe bone defects due to trauma, cancer or aging, a huge demand for more effective treatments is one of the important challenges in clinical practice. Biomaterials for bone tissue engineering (BTE) is one of the appealing approach to enhance regenerative capability by combining several biocomponents like biomimetic materials and nanomaterials, cells, growth factors. Hydroxyapatite (HA) represents the most used based biomaterial for bone regeneration. However, there is still a crucial demand for new HA-based biomaterials satisfying clinical needs in terms of improved osteointegration and osteoregeneration. Here we show the synergic application of two nanomaterials, i.e., a fluorogenic hyaluronan nanogel (hyaluronic acid with Rhodamine B, HyRB) and a class of theranostic core–shell silica nanoparticles (PluSNPs) integrated into MgHA-type I collagen-based scaffolds. This novel biomaterial (HyRB/PluSNPs doped MgHA) showed improved performance in osteoregeneration, both for osteoconductivity and osteoinductivity; furthermore, the HyRB/PluSNPs nanomaterials can act as contrast agent for fluorescence imaging and have a potential for targeted drug delivery and for phototherapy. Results pave the way for the development of new multifunctional biomat
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.